Vivus Qsymia Launch Includes Strategy To Overcome Medicare Hurdles
Executive Summary
Company reports several hundred prescribers have completed online training as part of the Risk Evaluation and Mitigation Strategy for the weight loss drug, which is moving toward a fourth-quarter entry into the marketplace.
You may also be interested in...
Vivus’ Qsymia Sales Still Slim, Even As Costs Bulge
The obesity drug maker is pulling out all the stops to make its drug more accessible to patients, but several roadblocks still stand in the way of the drug banking meaningful sales revenue. Meanwhile, the launch and a post-marketing trial of Qsymia are adding up in terms of cost.
Qsymia, Belviq Make Progress With Aetna, But Coverage Remains Long-Term Challenge
Aetna has issued a revised clinical policy bulletin that includes Qsymia and Belviq among the drugs it considers to be “medically necessary weight reduction medications” when a series of criteria are met.
FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs
Agency offers perspective in New England Journal of Medicine that lays out the case for careful use of drugs in a space with medical need but a long history of products with toxic side effects.